British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...

GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

The pharma’s lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

GSK filed two lawsuits at the US District of Delaware on 15 October saying that Moderna’s mRNA vaccine product Spikevax ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

UK pharma major GSK has sued USA-based Moderna this week, accusing the latter of violating patents protecting GSK’s COVID-19 ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

英国制药公司葛兰素史克（GlaxoSmithKline）在特拉华州的一家联邦法院对美国Moderna公司提起诉讼。GSK声称Moderna在开发和销售其COVID-19疫苗Spikevax的过程中侵犯了GSK与信使RNA（mRNA）技术相关的专利。 该诉讼声称，Moderna用于将mRNA传递到细胞中的脂质纳米粒子侵犯了GSK的专利。根据GSK的说法，这些专利是Moderna疫苗产品所使用的mRN ...

近日，辉瑞宣布终止针对呼吸道合胞病毒（RSV）治疗药物sisunatovir的开发。根据10月7日ClinicalTrials.gov网站的更新，辉瑞已经停止了两项关于sisunatovir治疗RSV感染的临床研究。

智通财经APP获悉，葛兰素史克 (GSK.US)周二表示，其呼吸道合胞病毒 (RSV)疫苗在接种后的三个季度都具有保护作用。经季节性因素调整后的数据显示，这种用于老年人的疫苗的三个季度累积有效性为62.9%。

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to ...